LifeVantage Co. (NASDAQ:LFVN) Short Interest Up 137.5% in February

LifeVantage Co. (NASDAQ:LFVN) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,410,000 shares, an increase of 137.5% from the January 31st total of 593,800 shares. Approximately 14.0% of the company’s stock are sold short. Based on an average trading volume of 214,300 shares, the days-to-cover ratio is currently 6.6 days.

LifeVantage Trading Up 3.6 %

LFVN opened at $17.17 on Friday. LifeVantage has a 1-year low of $5.22 and a 1-year high of $27.38. The stock’s fifty day simple moving average is $20.10 and its 200 day simple moving average is $14.87. The stock has a market cap of $215.50 million, a PE ratio of 30.66 and a beta of 0.84.

LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.

LifeVantage Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 3rd will be given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Monday, March 3rd. LifeVantage’s payout ratio is 28.57%.

Insiders Place Their Bets

In other news, Director Raymond B. Greer sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the sale, the director now owns 99,288 shares in the company, valued at $2,000,653.20. This represents a 7.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 20.65% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LFVN. Capital Management Corp VA bought a new position in LifeVantage during the 3rd quarter worth $5,073,000. LPL Financial LLC increased its position in LifeVantage by 301.0% during the 4th quarter. LPL Financial LLC now owns 211,039 shares of the company’s stock worth $3,700,000 after buying an additional 158,405 shares during the period. Ancora Advisors LLC bought a new position in LifeVantage during the 4th quarter worth $1,138,000. EAM Investors LLC bought a new position in LifeVantage during the 4th quarter worth $1,056,000. Finally, Susquehanna International Group LLP increased its position in LifeVantage by 83.5% during the 4th quarter. Susquehanna International Group LLP now owns 128,082 shares of the company’s stock worth $2,245,000 after buying an additional 58,279 shares during the period. Institutional investors own 35.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LFVN. Lake Street Capital began coverage on LifeVantage in a research note on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective on the stock. Craig Hallum initiated coverage on LifeVantage in a research note on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price target on the stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.